Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Osteologix has completed patient enrollment in the early stage clinical trial of its improved osteoporosis compound, NBS-101. The company will now move to the treatment phase of the trial.
Subscribe to our email newsletter
NBS-101 is being studied as an improved formulation of strontium, which was recently approved in Europe, in the form of strontium ranelate, and launched in several European countries.
Preclinical studies suggest that a substantially lower dose of NBS-101 may deliver the same amount of active ingredient as the 2 gram dose used in the commercialized version currently available in European markets. The study seeks to identify the optimum dose for the new form of the drug.
“There are currently no US FDA-approved osteoporosis drugs that both increase bone formation and decrease bone resorption. Because of its distinct mechanism of action, and because it is in a new class of compounds, we anticipate that NBS-101 could lead to a safer drug with fewer side effects” said Charles Casamento, CEO and President of Osteologix.
The clinical trial was initiated on May 27, 2005 and is being conducted at Hvidovre Hospital in Copenhagen, Denmark.